BeyondSpring Reports First Quarter 2017 Financial Results
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative immuno-oncology cancer therapies, today announced its unaudited financial results for the first quarter ended March 31, 2017.
“During the quarter, we continued to make progress on our two most advanced clinical trials for our lead asset, Plinabulin, which includes a study for the prevention of chemotherapy-induced neutropenia and a study for increasing overall survival in patients with advanced Non-Small Cell Lung Cancer (“NSCLC”) who have measurable lung lesions,” said Dr. Lan Huang, Co-Founder, Chairman and CEO of BeyondSpring. “Our next data milestone, which is expected to be announced within the next six months, is the Phase 2 data from our neutropenia studies.”
“During the quarter, we continued to make progress on our two most advanced clinical trials for our lead asset, Plinabulin, which includes a study for the prevention of chemotherapy-induced neutropenia and a study for increasing overall survival in patients with advanced Non-Small Cell Lung Cancer (“NSCLC”) who have measurable lung lesions,” said Dr. Lan Huang, Co-Founder, Chairman and CEO of BeyondSpring. “Our next data milestone, which is expected to be announced within the next six months, is the Phase 2 data from our neutropenia studies.”